As such, a comprehensive analysis of the expression of CD20 in both healthy and B-cell lymphoma diagnosed dogs might also have a critical role in the development of a similar canine anti-CD20 immunotherapy. The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.